Integrative Diagnosis for SCD and Other RADs

ConditionsSickle Cell Disease Thalassaemia Congenital Dyserythropoietic Anemia (CDA)Enzyme Disorder; Anemia Spherocytosis, Hereditary Stomatocytosis Hemoglobin Disorder Anemia Due to Membrane Defect Rare Anemia Disorders

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorHospital Universitari Vall d'Hebron Research Institute

About this trial

INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.

Eligibility criteria

Qualifiers

Sickle cell disease

Thalassemic syndromes

Congenital dyserythropoietic anemia

Enzymopathy

Disqualifiers

Carrier traits in autosomal recessive hereditary anemias

Trial design

Treatments tested in this trial

Analysis of genetic modifiers
Disease phenotyping

Treatment groups

No treatment groups listed

Sponsors and collaborators

Hospital Universitari Vall d'Hebron Research Institute

Lead sponsor

Hospital Clinic of Barcelona

Collaborator

Institute for Bioengineering of Catalonia

Collaborator

Hospital Arnau de Vilanova, Lleida (Spain)

Collaborator

Source ClinicalTrials.gov